Main content start
JAMA Surgery Paper Published.
Our paper was published today. There are fewer and fewer reasons to avoid using HepC+ liver donors. Reevaluating Liver Donor Risk in the Era of Improved HCV Treatment
Over 50 000 people die of liver disease in the US annually.1 Liver transplant is a life-saving option for patients with liver failure, but demand outstrips supply.2 Hepatitis C virus (HCV) has historically been a significant cause of organ discard. However, approval of direct-acting antiviral medications (DAAs) revolutionized HCV treatment and changed perceptions of transplant risk.3 This study examines the risk of graft failure associated with donors with HCV infection before and after the introduction of DAAs.
https://jamanetwork.com/journals/jamasurgery/fullarticle/2797094